197 related articles for article (PubMed ID: 24352250)
1. Targeting cisplatin-resistant human tumor cells with metabolic inhibitors.
Sullivan EJ; Kurtoglu M; Brenneman R; Liu H; Lampidis TJ
Cancer Chemother Pharmacol; 2014 Feb; 73(2):417-27. PubMed ID: 24352250
[TBL] [Abstract][Full Text] [Related]
2. Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism.
Ai Z; Lu Y; Qiu S; Fan Z
Cancer Lett; 2016 Apr; 373(1):36-44. PubMed ID: 26801746
[TBL] [Abstract][Full Text] [Related]
3. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer.
Chattopadhyay S; Machado-Pinilla R; Manguan-García C; Belda-Iniesta C; Moratilla C; Cejas P; Fresno-Vara JA; de Castro-Carpeño J; Casado E; Nistal M; Gonzalez-Barón M; Perona R
Oncogene; 2006 Jun; 25(23):3335-45. PubMed ID: 16462770
[TBL] [Abstract][Full Text] [Related]
4. The kinase RSK2 modulates the sensitivity of ovarian cancer cells to cisplatin.
van Jaarsveld MT; Blijdorp IC; Boersma AW; Pothof J; Mathijssen RH; Verweij J; Wiemer EA
Eur J Cancer; 2013 Jan; 49(2):345-51. PubMed ID: 23041051
[TBL] [Abstract][Full Text] [Related]
5. The inhibition of miR-21 promotes apoptosis and chemosensitivity in ovarian cancer.
Chan JK; Blansit K; Kiet T; Sherman A; Wong G; Earle C; Bourguignon LY
Gynecol Oncol; 2014 Mar; 132(3):739-44. PubMed ID: 24472409
[TBL] [Abstract][Full Text] [Related]
6. Role of 14-3-3σ in resistance to cisplatin in non-small cell lung cancer cells.
Cetintas VB; Tetik A; Cok G; Kucukaslan AS; Kosova B; Gunduz C; Veral A; Eroglu Z
Cell Biol Int; 2013 Jan; 37(1):78-86. PubMed ID: 23339090
[TBL] [Abstract][Full Text] [Related]
7. Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy.
Zhang XY; Zhang M; Cong Q; Zhang MX; Zhang MY; Lu YY; Xu CJ
Int J Biochem Cell Biol; 2018 Feb; 95():9-16. PubMed ID: 29247711
[TBL] [Abstract][Full Text] [Related]
8. Dihydrodiol dehydrogenases regulate the generation of reactive oxygen species and the development of cisplatin resistance in human ovarian carcinoma cells.
Chen J; Adikari M; Pallai R; Parekh HK; Simpkins H
Cancer Chemother Pharmacol; 2008 May; 61(6):979-87. PubMed ID: 17661040
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of glycolysis enhances cisplatin-induced apoptosis in ovarian cancer cells.
Loar P; Wahl H; Kshirsagar M; Gossner G; Griffith K; Liu JR
Am J Obstet Gynecol; 2010 Apr; 202(4):371.e1-8. PubMed ID: 20138251
[TBL] [Abstract][Full Text] [Related]
11. Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells.
Zhang T; Guan M; Jin HY; Lu Y
Gynecol Oncol; 2005 May; 97(2):501-7. PubMed ID: 15863151
[TBL] [Abstract][Full Text] [Related]
12. [Relationship between nucleotide excision repair gene ERCC1 and resistance to cisplatin in ovarian cancer].
Liu GY; Qu QX; Mi RR; Qi J
Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):184-7. PubMed ID: 18756932
[TBL] [Abstract][Full Text] [Related]
13. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.
Selvakumaran M; Pisarcik DA; Bao R; Yeung AT; Hamilton TC
Cancer Res; 2003 Mar; 63(6):1311-6. PubMed ID: 12649192
[TBL] [Abstract][Full Text] [Related]
14. Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance.
Cho JM; Manandhar S; Lee HR; Park HM; Kwak MK
Cancer Lett; 2008 Feb; 260(1-2):96-108. PubMed ID: 18036733
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
Jain N; Lam YM; Pym J; Campling BG
Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
[TBL] [Abstract][Full Text] [Related]
16. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines.
Wang W; Ke S; Chen G; Gao Q; Wu S; Wang S; Zhou J; Yang X; Lu Y; Ma D
Oncol Rep; 2004 Dec; 12(6):1365-70. PubMed ID: 15547764
[TBL] [Abstract][Full Text] [Related]
17. Ovarian carcinoma cells with low levels of beta-F1-ATPase are sensitive to combined platinum and 2-deoxy-D-glucose treatment.
Hernlund E; Hjerpe E; Avall-Lundqvist E; Shoshan M
Mol Cancer Ther; 2009 Jul; 8(7):1916-23. PubMed ID: 19567816
[TBL] [Abstract][Full Text] [Related]
18. MiR-155 inhibits the sensitivity of lung cancer cells to cisplatin via negative regulation of Apaf-1 expression.
Zang YS; Zhong YF; Fang Z; Li B; An J
Cancer Gene Ther; 2012 Nov; 19(11):773-8. PubMed ID: 22996741
[TBL] [Abstract][Full Text] [Related]
19. Annexin XI is associated with cisplatin resistance and related to tumor recurrence in ovarian cancer patients.
Song J; Shih IeM; Salani R; Chan DW; Zhang Z
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6842-9. PubMed ID: 17982121
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of Ras-related protein Rab 5C-dependent endocytosis and glycolysis in cisplatin-resistant ovarian cancer cell lines.
Jin L; Huo Y; Zheng Z; Jiang X; Deng H; Chen Y; Lian Q; Ge R; Deng H
Mol Cell Proteomics; 2014 Nov; 13(11):3138-51. PubMed ID: 25096996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
